Targeted Therapy Drugs for Waldenstrom Macroglobulinemia

In recent years, new drugs that target specific parts of cancer cells have been developed. These targeted drugs work differently from standard chemotherapy drugs, and they can have different side effects than chemo. They can be used instead of chemo or along with it, in some situations.

Some targeted drugs can be useful in treating Waldenstrom macroglobulinemia.

Bruton tyrosine kinase (BTK) inhibitors

BTK inhibitors are drugs that block a protein inside lymphoma cells called Bruton tyrosine kinase. This protein normally helps the lymphoma cells grow and survive.

 Examples of BTK inhibitors include:

  • Acalabrutinib (Calquence)
  • Ibrutinib (Imbruvica) alone or in combination with immunotherapy
  • Orelabrutinib
  • Pirtobrutinib (Jaypirica)
  • Tirabrutinib
  • Zanubrutinib (Brukinsa)

These drugs are taken by mouth as pills, typically once or twice a day.

Possible side effects

Common side effects of BTK inhibitors include:

  • Diarrhea
  • Rash
  • Muscle and bone pain
  • Fatigue
  • Cough
  • Bruising
  • Low blood cell counts

Less common but more serious side effects can include:

  • Bleeding
  • Serious infections
  • Heart rhythm problems
  • Skin cancer

Proteasome inhibitors

Proteasome inhibitors stop enzyme complexes (proteasomes) inside cells from breaking down proteins inside the cancer cells that are no longer needed. When this protein waste builds up, the cancer cells can’t grow and divide, causing them to die.

Examples of proteasome inhibitors include:

  • Bortezomib (Velcade)
  • Ixazomib (Ninlaro), sometimes in combination with immunotherapy and steroids
  • Carfilzomib (Kyprolis)

These drugs can be given by mouth (ixazomib), injected under the skin (bortezomib), or as an infusion into a vein (bortezomib and carfilzomib).

Possible side effects

Common side effects of proteasome inhibitors are:

  • Low blood counts
  • Nausea
  • Loss of appetite

They can also damage nerves, causing pain in the feet and legs called peripheral neuropathy. This nerve damage usually gets better after the drug is stopped, but it might not go away completely.

mTOR inhibitors

mTOR inhibitors block a cell protein known as mTOR, which normally helps cells grow and divide into new cells.

Everolimus (Afinitor) is used more often to treat some other types of cancer, but it has been shown to be useful in treating Waldenstrom macroglobulinemia after other treatments have been tried.

This drug is taken daily as a pill.

Possible side effects

Common side effects include:

  • Fatigue (tiredness)
  • Mouth pain
  • Rash
  • Diarrhea
  • Infections

BCL-2 inhibitors

These drugs attack BCL-2, a protein that can help leukemia cells live longer.

Venetoclax (Venclexta) is one example. It may be used to treat Waldenstrom macroglobulinemia after other drugs have been tried.

These drugs are given by mouth as a tablet, usually once daily.

Possible side effects

The most common side effects of BCL-2 inhibitors are:

  • Fever
  • Feeling tired or weak
  • Low appetite
  • Nausea
  • Diarrhea
  • Low blood counts
  • Swelling
  • Skin rash
  • Changes to some blood tests, which may need to be watched while getting the drug

More information about targeted therapy

To learn more about how targeted drugs are used to treat cancer, see Targeted Cancer Therapy.

To learn about some of the side effects listed here and how to manage them, see Managing Cancer-related Side Effects.

side by side logos for American Cancer Society and American Society of Clinical Oncology

Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).

Buske C, Castillo JJ, Abeykoon JP, et al. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients. Semin Hematol. 2023;60(2):73-79.

Buske C, Dimopoulos MA, Grunenberg A, et al. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia. J Clin Oncol. 2023;41(14):2607-2616.

Buske C, Tedeschi A, Trotman J, et al. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. J Clin Oncol. 2022;40(1):52-62.

Castillo JJ, Treon SP. Chapter 92: Waldenstrom Macroglobulinemia/ Lymphoplasmacytic Lymphoma. In: Hoffman R, Benz EJ, Silberstein LE, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA. Elsevier; 2023.

Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood. 2019;134(23):2022-2035.

Dimopoulos MA, Opat S, D'Sa S, et al. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. J Clin Oncol. 2023;41(33):5099-5106.

Gertz MA. Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management. Am J Hematol. 2025;100(6):1061-1073.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma. v.1.2026-June 24, 2025. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf on August 5, 2025.

Rajkumar SV, Dispenzieri A. Chapter 101: Multiple myeloma and related disorders. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa. Elsevier: 2019.

Treon SP, Gustine J, Meid K, et al. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2018;36(27):2755-2761.

Treon SP, Tedeschi A, San-Miguel J, et al. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. Semin Hematol. 2023;60(2):97-106.

Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015;372(15):1430-1440.

Last Revised: November 17, 2025

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.